title: Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
abstract: BACKGROUND
  To investigate the effects of Glimepiride on blood glucose in patients with newly diagnosed type 2 diabetes mellitus (T2DM) in connection with plasma lipoproteins and plasminogen activity.
  
  
  METHODS
  A total of 565 T2DM patients were received Glimepiride (n=333) or Glibenclamide (n=232) for 12 weeks. We observed the level of blood glucose (BG), glycated hemoglobin (HbA1C), the insulin resistance (IR) state, plasma lipoproteins, tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type I (PAI-1) before and after a 12 weeks of treatment.
  
  
  RESULTS
  After 12 weeks with Glimepiride treatment, significant reductions were observed in fasting blood glucose (FBG) and 2-h postprandial BG(PBG), HbA1C (from 8.60+/-3.10 to 7.10+/-1.60%) and HOMA-IR (from 4.11+/-0.85 to 2.42+/-0.91%). The level of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly decreased, whereas that of high-density lipoprotein (HDL) was increased markedly with statistical significance. In addition, there was an obvious improvement in t-PA activity (from 0.225+/-0.11 to 0.457+/-0.177IU/ml); whereas the PAI-1 activity was decreased significantly (from 0.898+/-0.168 to 0.533+/-0.215AU/ml). No significant changes were observed in plasma lipoprotein profiles and plasminogen activity in Glibenclamide receiving group.
  
  
  CONCLUSIONS
  Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity.
authors.affiliation: Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, PR China. xudanyan02@sina.com
authors.forename: Dan-yan
authors.initials: DY
authors.lastname: Xu
authors.forename: Shui-Ping
authors.initials: SP
authors.lastname: Zhao
authors.forename: Qiu-xia
authors.initials: QX
authors.lastname: Huang
authors.forename: Wei
authors.initials: W
authors.lastname: Du
authors.forename: Yu-hua
authors.initials: YH
authors.lastname: Liu
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Xiao-mei
authors.initials: XM
authors.lastname: Xie
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005905:Glyburide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000097:blood; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; D013453:Sulfonylurea Compounds; D010959:Tissue Plasminogen Activator; C057619:glimepiride